Open Science, Open Intelligence, Open Business – Why MAIVAN is an AI-first Public Benefit Corporation

Fast Reader’s Summary

MAIVAN is transforming orthopedic healthcare by integrating clinically validated AI solutions directly into clinical workflows. Here’s what makes us stand out:

Company Vision

MAIVAN aims to revolutionize orthopedic diagnostics and treatment by embedding AI tools into existing hospital systems, enhancing accuracy while reducing costs. Their platform connects medical experts with data scientists to deliver value-based care.

Market Opportunity

• The global AI healthcare market is projected to grow from $19B (2023) to nearly $190B by 2030 (38-40% CAGR)
• Orthopedic care represents a high-impact opportunity, with musculoskeletal disorders affecting 1.7B people globally
• The digital MSK care market is valued at $4.4B (2024) with projected 17.7% annual growth

Competitive Edge

MAIVAN differentiates itself through:

1. Crowd-Validation: Algorithms are tested by a network of 100,000+ orthopedic surgeons before deployment
2. Comprehensive Platform: Offers a curated marketplace of AI solutions with clinician feedback loops
3. Value-Based Model: Revenue tied to patient outcomes, not just usage fees
4. Strategic Partnerships: Collaborations with orthopedic organizations (EFORT, AOSSM) and tech leaders (Google, NVIDIA)

Technology Highlights

• Privacy-Preserving Collaboration: Uses federated learning to train AI without moving sensitive patient data
• Seamless Integration: Connects to existing hospital systems (PACS, EHRs) with minimal workflow disruption
• AI Marketplace: Hosts various orthopedic AI solutions in one accessible platform
• Innovative Data Generation: Creates synthetic medical images to overcome data scarcity challenges

Business Model

MAIVAN generates revenue through software licensing, marketplace transactions, and performance-based payments—all designed to align with healthcare’s shift toward value-based care.

MAIVAN is uniquely positioned at the intersection of validated AI, orthopedic specialization, and value-based healthcare delivery, aiming to improve patient outcomes while reducing healthcare costs.

Company Overview

MAIVAN leverages advanced cloud AI platforms to seamlessly integrate clinically validated intelligence into orthopedic care at the point of care​. By embedding AI into existing hospital workflows, MAIVAN aims to increase diagnostic accuracy and treatment efficiency while reducing costs. This AI-first approach ensures providers have decision support tools at their fingertips without disrupting routine.

MAIVAN is an AI-driven orthopedic healthcare company dedicated to transforming musculoskeletal care through technology. Key highlights include:

• Mission – Revolutionize orthopedic diagnostics and treatment planning by integrating clinically validated AI solutions into healthcare workflows​. By enhancing diagnostic accuracy and optimizing treatment plans, we strive to improve surgical outcomes for patients.

• Vision – Lead the world in orthopedic AI innovation by building a collaborative platform where medical experts and data scientists unite to deliver value-based care. MAIVAN envisions every orthopedic clinician empowered with AI tools that make care more precise, personalized, and efficient.

• Value Proposition – Deliver better outcomes at lower costs. MAIVAN tackles data scarcity and low trust in medical AI by crowd-validating algorithms with clinicians, ensuring they are safe and effective. This approach yields significant improvements in clinical practice – reducing diagnostic errors, streamlining surgical planning, and lowering complication rates​. For healthcare providers, that means improved patient results and cost savings, all through an easily adoptable AI platform.

Market Opportunity

The AI healthcare market is experiencing explosive growth. As shown, the U.S. AI in healthcare sector alone is projected to expand at ~35% CAGR through 2030, paralleling global trends​.

This surge is fueled by increasing data availability, rising healthcare demand, and breakthroughs in AI technology, which together create a massive opportunity for solutions like MAIVAN. In fact, analysts estimate the global AI health market will reach nearly $188 billion by 2030​, underlining the vast opportunity MAIVAN is poised to capture.

• High Growth – The global AI in healthcare market (~$19 billion in 2023) is expected to soar to around $180–190 billion by 2030 (38–40% CAGR)​. This growth outpaces most other industries and reflects a transformative shift – AI is moving healthcare from reactive to proactive and predictive models. The demand for AI is driven by the need to enhance efficiency and patient outcomes at scale.

• Rising Adoption – Healthcare providers are rapidly embracing AI solutions. 79% of healthcare organizations report they are already using AI technology in some form​. Importantly, these early adopters are seeing value: the average return on investment for AI in healthcare is estimated at 3.2× within 14 months (i.e. $3.20 back for every $1 invested)​. This high ROI is accelerating adoption – from AI reading radiology scans to AI predicting patient deterioration – and indicates providers are increasingly confident in AI’s benefits.

• Key Market Drivers – Several forces are propelling this trend.
  • First, the explosion of healthcare data (from electronic health records, medical images, wearables, genomics) has far outstripped human clinicians’ capacity to interpret it all​. AI tools can sift big data to find actionable insights, enabling more informed clinical decisions.
  • Second, a shortage of healthcare workers (a projected 10 million global deficit by 2030​) is pressuring health systems to do more with less – AI augments staff by automating routine tasks and flagging priorities.
  • Third, shifting payment models (insurers and governments pushing for value and outcomes) incentivize hospitals to adopt technologies that improve quality and reduce waste.
  • Lastly, the COVID-19 pandemic spurred digital health acceptance, making both patients and providers more comfortable with AI and telehealth solutions.

• Orthopedic Focus – Within healthcare AI, orthopedic care is a high-impact niche ready for innovation. Musculoskeletal disorders affect over 1.7 billion people worldwide, making them the leading cause of disability globally​.
  • The need for better orthopedic diagnostics and treatments is immense – e.g. missed fracture diagnoses or suboptimal surgical plans can lead to costly complications.
  • The digital health market for musculoskeletal (MSK) care was valued at $4.4 billion in 2024 and is projected to grow ~17.7% annually through 2030​.
  • Orthopedics is heavy on imaging and repetitive decision-making (fracture classifications, implant selections), areas where AI excels. From automatically detecting fractures on X-rays to predicting post-surgery outcomes, AI can drive major improvements.
  • Yet adoption in orthopedics lags fields like radiology – representing a ripe opportunity for MAIVAN to lead. By targeting this substantial sub-market, MAIVAN can tap into a large patient population and an area of significant spending (global orthopedic care costs hundreds of billions per year), with relatively few AI solutions currently available.

Competitive Landscape

The healthcare AI landscape features many players, but MAIVAN stands out in a largely fragmented field. We categorize the competition and MAIVAN’s differentiation as follows:

• Point Solution Startups – A number of startups offer narrow AI tools for orthopedics (especially in medical imaging). For example, AI software for fracture detection has seen dozens of entrants – a recent review identified 21 commercially available AI tools for fracture detection from 15 different vendors​ (e.g. AZmed’s Rayvolve for trauma X-rays, Gleamer’s BoneView, Imagen’s OsteoDetect for wrist fractures). These solutions demonstrate that AI can improve detection sensitivity and save radiologists time, but each covers only a specific use-case and must be integrated one by one into clinical practice. None provide a comprehensive platform or address the validation bottleneck; in fact, many tools have limited real-world clinical testing. MAIVAN, by contrast, offers a suite of solutions on one platform with guaranteed clinical validation, reducing the adoption friction for hospitals.

• Imaging & IT Platforms – Some healthcare IT companies and consortia are building marketplaces to aggregate AI algorithms (for example, the deepcOS platform and Sectra’s Amplifier Marketplace allow hospitals to access multiple radiology AI apps in one place). These facilitate integration, but lack independent clinical validation – they are essentially app stores. MAIVAN’s approach goes further by crowd-validating each algorithm with orthopedic experts before it ever hits the marketplace. This community curation means providers on MAIVAN get algorithms that are not only integrated, but proven in clinical settings. Additionally, MAIVAN’s focus on orthopedics allows curation of specialty-specific tools (fracture detection, bone tumor AI, surgical planning aids) that general marketplaces might not prioritize.

• Large Tech and Medtech – Tech giants (Google, Microsoft, IBM) and established medical device firms (e.g. Stryker, Johnson & Johnson) are investing in AI for healthcare. Their efforts (like Google’s healthcare AI research or J&J’s orthopedic robotic surgery with data analytics) underscore the market’s potential. However, these players often tackle broader problems or use AI to enhance their own products, rather than create an open collaborative network. In orthopedics specifically, no incumbent has achieved what MAIVAN proposes – a neutral platform bringing many stakeholders together. Moreover, big firms face regulatory and trust hurdles too; for instance, IBM Watson Health struggled and was ultimately scaled down. MAIVAN’s nimbleness and singular focus on orthopedics give it an edge to capture this niche. Notably, the industry trend is moving toward acquiring AI innovations rather than building in-house – e.g. Medtronic’s 2020 acquisition of Medicrea brought it an AI-driven spine surgery planning platform​.

• MAIVAN’s Differentiation

• 1) Clinically Validated & Trusted: MAIVAN is not just another AI tool, but a validation network. By enabling “crowd-validation” of algorithms through a community of 100k orthopedic surgeons worldwide, MAIVAN ensures its solutions meet the highest clinical standards before deployment​. This addresses the key trust barrier head-on – a surgeon is far more likely to use an AI tool that has been vetted by peers and endorsed by respected societies.

• 2) Comprehensive Value Network: MAIVAN combines a curated marketplace of multiple solutions with a feedback loop (developers ↔ clinicians) and even a data generation service. This holistic approach means we can serve hospitals as a one-stop shop for orthopedic AI needs, where competitors offer piecemeal tools.

• 3) Value-Based Business Model: Unlike many AI providers who charge upfront or per-use fees irrespective of outcomes, MAIVAN aligns its success with patient outcomes (via performance-based contracts)​. This is appealing to customers and sets us apart philosophically – we win only when the hospital and patients win, which isn’t the case for most competitors.

• 4) Partnerships & Ecosystem: Our early partnership with leading orthopedic organizations (like EFORT in Europe and AOSSM in the US) provides credibility and network effects that newcomers would find hard to match​. Additionally, MAIVAN’s collaboration with cloud and hardware leaders (Google, NVIDIA) ensures we have a scalable, cutting-edge infrastructure from day one, accelerating go-to-market​. In summary, MAIVAN occupies a blue ocean at the intersection of validated AI, orthopedic specialization, and value-based delivery – a space where we currently see no direct competitors offering the same integrated value proposition.

Business Model

MAIVAN’s business model is built around Value-Based Healthcare (VBHC) principles​, meaning we succeed when our clinical customers and patients see measurable improvements.

Key elements of the model include:

• Multi-Stream Revenue – We generate revenue through several streams, balancing upfront and recurring sources​:

• AI Software Licensing: Healthcare providers (hospitals/clinics) pay subscription fees to access MAIVAN’s AI platform. This could be tiered (e.g. based on number of users or analysis volume) or enterprise licenses for whole hospital systems. The subscription grants use of a suite of validated AI tools and the data marketplace.

• Marketplace Transactions: For third-party AI solutions or datasets available through MAIVAN, we earn a commission on each transaction/license. For example, if a research group’s fracture-detection algorithm is licensed by a hospital via our platform, MAIVAN takes a percentage of that licensing fee. This incentivizes us to curate high-quality offerings and actively facilitate matches between AI developers and clinicians.

• Performance-Based Payments: In some cases, MAIVAN will enter outcome-based contracts with healthcare payers or providers​. Under these agreements, our revenue is tied to achieving specific results (e.g. reduction in surgical revision rates or cost savings in orthopedic episodes of care). For instance, a hospital might pay a bonus or higher fee only if our AI bundle helps reduce their joint surgery complication rate by X%. This aligns with emerging value-based care programs and makes adoption risk-free for customers.

• Pricing Strategy – Flexibility is a core strategy. We will tailor pricing to the customer’s size and value gained. A small orthopedic clinic might opt for a pay-per-use model for specific AI analyses, whereas a large hospital network might prefer an annual subscription for unlimited use across multiple departments. Our pricing will be competitive with alternative solutions (for example, pricing an AI analysis at a fraction of what a radiologist’s time would cost for the same task, thus demonstrating immediate cost benefit). By also offering outcome-tied pricing, we differentiate ourselves – essentially giving a “money-back guarantee” in terms of performance. This approach lowers initial barriers: a hospital can try MAIVAN with minimal financial risk and scale up usage as benefits are proven.

• Scalability & Margins – MAIVAN is inherently scalable as a cloud-based software platform. Once our AI models and marketplace are developed, the cost to onboard additional hospitals is relatively low – primarily integration and customer support. We leverage Google Cloud and NVIDIA’s infrastructure to deploy globally with reliability and speed​. As more users join, the network becomes more valuable (more data and feedback improves the AI, attracting more users in turn). This network effect gives upside to scale. Financially, our gross margins are high (software margins ~75%+) since the product is digital​. While we will incur costs for cloud computing and maintaining data pipelines, these scale sub-linearly compared to the revenue from additional customers. Over time, we expect strong operating leverage – i.e. our operating costs growing much slower than revenues – which is a hallmark of successful SaaS platforms.

• Customer Segments & Scalability – MAIVAN serves a multi-sided market​:
  • On one side, Healthcare Providers (orthopedic hospitals, surgical centers, trauma clinics) are our primary users and source of subscription revenue. They gain diagnostic tools and decision support.

• On the other side, AI Solution Developers (e.g. startups, research labs) and Medical Device Companies contribute content to our platform – their algorithms or data can reach customers through MAIVAN​. We effectively act as a distribution channel for them, and in return share revenue (commission model above). This makes MAIVAN attractive to smaller AI innovators who lack sales channels, as well as big device companies that want to offer AI enhancements with their products (e.g. an implant maker providing an AI surgical planning app via MAIVAN).

• Additionally, Payers/Insurers are indirect stakeholders​. While they may not pay us directly, they influence adoption. If we can demonstrate that MAIVAN’s solutions reduce costs (fewer complications, faster recovery), insurers might incentivize or even mandate providers to use our platform. Eventually, this could open a revenue path where insurers or government health systems contract with MAIVAN to implement our solutions across their provider networks as part of cost-saving initiatives.

• This multi-sided approach expands our scalability: we aren’t limited to selling hospital by hospital; we can also grow by onboarding new solutions (making the platform more valuable and drawing more providers) and potentially through payer-driven programs (accessing many providers at once).

Legal Structure

MAIVAN operates as both a non-profit Swiss Association for validation and a commercial AG (Public Benefit Corporation) for deployment​.

This setup helps us maintain the trust and compliance of a neutral validator while also being able to commercialize and scale globally.

Technology and Innovation

MAIVAN’s platform is at the cutting edge of healthcare technology, uniquely combining AI, big data, and collective intelligence. Key technological differentiators include:

• “Crowd-Validation” Platform – A signature innovation of MAIVAN is leveraging the power of the crowd – specifically a global network of orthopedic professionals – to validate AI solutions​maivan.ch. Before any algorithm is widely deployed, it is tested across multiple hospitals and reviewed by many independent surgeons. Through our partnership with leading orthopedic and trauma associations, we have access to over 100,000 orthopedic surgeons worldwide who can participate in evaluating AI outputs on cases. For example, an AI might predict fracture classifications or surgical approaches – MAIVAN’s platform enables surgeons in the network to review those predictions against their own judgment. This yields a “crowd consensus” on the AI’s accuracy and utility. We incorporate this feedback to improve the algorithms (“human-in-the-loop” refinement) and only approve tools that meet high clinical standards. This process is akin to a massive distributed clinical trial or peer-review, and is unique to MAIVAN. It not only ensures clinical efficacy of our tools but also fosters buy-in: surgeons who help validate are more likely to trust and advocate the AI in practice. Responsible AI development is also promoted – biases or failure modes are caught early by diverse experts, and the AI can be adjusted accordingly, leading to safer outcomes.

• Privacy-Preserving Collaboration – Healthcare data privacy is paramount, so MAIVAN employs cutting-edge techniques to enable AI training and validation without compromising patient privacy. We utilize federated learning, where our AI models can be trained on data residing in multiple hospital sites without raw data ever leaving those sites​. In practice, this means a model can learn from, say, Hospital A’s and Hospital B’s X-rays, but only encrypted parameter updates travel across the network – not the patient images themselves. Each hospital’s data stays secure behind its firewall, and MAIVAN aggregates the learnings. This approach allows us to leverage large, diverse datasets (improving model accuracy across populations) while staying compliant with regulations like HIPAA and GDPR. Additionally, all data and model transactions are secured with robust encryption. Our integration with hospitals is via secure APIs and cloud connectors that have been vetted for security. By design, MAIVAN avoids creating any central vulnerable trove of patient data – we bring the AI to the data, not vice versa. This gives comfort to IT departments and patients that data security is maintained.

• Seamless Workflow Integration – A great AI tool is useless if it’s hard to use. MAIVAN’s technology is built to integrate smoothly into existing clinical workflows​. Our platform can connect to hospital PACS (Picture Archiving and Communication Systems for images) and EHRs through standard interfaces. For example, when a new X-ray is taken, a MAIVAN AI algorithm can automatically analyze it in the cloud and send the result (e.g. “suspected distal radius fracture highlighted”) into the radiologist’s viewer or the orthopedic surgeon’s dashboard within seconds. Similarly, our surgical planning AIs can plug into pre-operative planning software surgeons already use. We design our user interfaces with clinicians, ensuring they are intuitive (e.g. showing heatmaps on images, providing risk scores in plain language). This point-of-care delivery is often via web portal or integrated app – accessible on a hospital workstation or even a surgeon’s tablet. By meeting doctors where they are, we reduce change management hurdles. In short, MAIVAN’s tech augments doctors’ abilities without adding hassle, which is crucial for adoption.

• AI & Data Marketplace – At MAIVAN’s core is a marketplace that hosts a variety of AI solutions (developed in-house or by third parties) for orthopedic care. Think of it as an “app store” for vetted medical AI. A clinician using MAIVAN can access tools for imaging diagnostics, predictive modeling, or surgical guidance all in one place. To fuel these algorithms, MAIVAN provides rich data resources: we have developed advanced fracture simulation technology to generate synthetic medical images on demand​. For example, if an algorithm needs more training cases of a rare tibial fracture, our system can produce lifelike X-ray or CT images with those fracture patterns. This effectively gives us unlimited training data and helps overcome the typical data scarcity in AI (where getting thousands of labeled medical images is a bottleneck). All synthetic data is tagged and traceable via blockchain tokens (NFTs) to maintain provenance​ – data contributors (like a hospital providing real anonymized cases) can even be compensated through this mechanism, creating a fair data economy. The marketplace doesn’t just list algorithms; it also manages the licensing of data and models securely (smart contracts for usage rights) and tracks performance metrics of each algorithm in real-world use. This transparency builds trust in the ecosystem – users see which AI tools perform best on which types of cases.

• Continuous Innovation Loop – MAIVAN’s platform itself is constantly learning and improving. Each time our AI is used in practice, we gather anonymized feedback: Was the AI’s recommendation followed? How did the patient outcome turn out? This real-world evidence feeds back into our validation and R&D cycle (with user permission and ethical oversight). Moreover, our marketplace model invites external innovation – we actively encourage researchers and startups to bring new algorithms to MAIVAN. Our validation service and distribution channel is a big attraction for them (we handle the “last mile” of getting AI into doctors’ hands). In this way, MAIVAN acts as an innovation hub: we might host a competition (hackathon or “Grand Challenge”) on a tough orthopedic problem, engage the global AI community, and quickly channel the best solutions into clinical testing through our network. This keeps MAIVAN on the forefront of new developments. We’ve also partnered with global initiatives (such as the U.S.-based Coalition for Health AI) to remain aligned with best practices and standards​. Technologically, our use of top-tier infrastructure (Google Cloud for scalability, NVIDIA for AI acceleration) means we can iterate fast – deploying updates or new models across our network with a click. This agility is a major advantage in a field where evidence and technology are evolving quickly.

Risks and Mitigation

We recognize several potential risks in this venture and have strategies in place to mitigate each:

• Regulatory & Compliance Risk
  • Risk: As a medical AI provider, MAIVAN’s products likely require regulatory clearance (CE marking in EU as a Medical Device Software under MDR, FDA approval as AI-based diagnostic aid, etc.). Regulatory timelines can be long, and changes (like new AI-specific regulations) could impose additional requirements.
  • Mitigation: MAIVAN has proactively structured itself to excel at compliance. Our non-profit arm is essentially operating as a Conformity Assessment Body in anticipation of the EU AI Act​. This means we are conducting thorough validation and documentation (bias testing, risk management, clinical evaluation) for each algorithm from the start – building the exact evidence regulators need. Our team includes regulatory experts familiar with FDA and EMA processes to navigate submissions efficiently. We are also aligning with initiatives like the Coalition for Health AI to stay ahead of regulatory expectations. In short, we treat regulatory approval as a core competency, not an afterthought – turning a potential barrier into a MAIVAN strength. Early engagement with regulators and adherence to standards (ISO 13485, IEC 62304 for software, etc.) ensures we won’t hit unexpected roadblocks.

• Clinical Adoption Risk
  • Risk: Gaining acceptance from doctors and clinicians can be challenging. Busy orthopedic surgeons might be skeptical of AI or reluctant to change established practices. If end-users don’t adopt the tools, revenue will suffer even if the tech is great. Mitigation: MAIVAN’s model is specifically designed to foster clinician buy-in. By involving surgeons in the development and validation process (crowd-validation), we create champions among end-users​. These surgeons effectively co-create the product, and thus are more likely to trust and advocate for it. We are also focusing initial efforts on tech-savvy opinion leaders in orthopedics who can influence peers. Moreover, we emphasize human-AI collaboration in our messaging – the AI is there to assist, not replace, the clinician. It’s a “second pair of eyes” or a smart assistant, which is a positioning more likely to be embraced. Our pilot studies will generate real-world evidence of improved outcomes (e.g. “AI reduced misdiagnoses by X%” or “saved Y hours per week for the surgical team”), which we will publish and share. Having peer-reviewed journal articles and conference presentations by respected surgeons using MAIVAN will go a long way to convince others. Finally, our intuitive integration means using MAIVAN adds minimal burden – when clinicians see they don’t have to substantially change their routine to get value from our AI, resistance will drop. We also plan to implement strong user training and support to ensure a smooth onboarding for each clinical team.

• Data Privacy & Security Risk
  • Risk: Working with sensitive patient data (images, records) could expose the company to data breaches or privacy violations if not handled properly. A major breach or non-compliance with privacy laws could derail trust and lead to legal penalties.
  • Mitigation: Data security is paramount in our design. By using federated learning and on-site deployment, we minimize central data storage​. Most patient data never leaves the hospital’s control; when data is shared (e.g. to our central analytics), it’s de-identified and often in aggregate or synthetic form. We implement state-of-the-art encryption for data in transit and at rest. Our systems undergo regular security audits and penetration testing. Compliance-wise, we are ensuring all practices meet HIPAA standards (in the US) and GDPR (in Europe) from day one. We’re also aware of forthcoming AI transparency requirements and are building auditable logs (using blockchain tech) of how data is used​. If a patient or hospital asks, we can definitively show the trace of their data usage. Cyber insurance will be in place as a backstop. Culturally, we train all employees on data handling protocols to prevent human error breaches. In summary, we take a defense-in-depth approach: reduce the data we hold, protect the data we must handle, comply with all regulations, and document everything. This greatly lowers the likelihood and impact of a security incident.

• Competitive Risk
  • Risk: The healthcare AI field is competitive and evolving fast. Larger companies or new startups could develop similar offerings, perhaps with more funding or existing market presence, which could threaten MAIVAN’s market share. Tech giants might also enter the fray directly in orthopedic AI.
  • Mitigation: While competition is inevitable in a hot space, MAIVAN’s strategy builds in defensibility. Our network and data effects create a high barrier to entry – for example, our growing database of validated cases and real-world performance data will be proprietary and would take years for a competitor to replicate. We are securing key partnerships (with surgeon associations, etc.) early; once those are formalized, a competitor would face an uphill battle to win the trust of the community. Also, by the nature of our model, any competitor would have to also commit to rigorous validation (slowing them down) or cut corners (which we believe customers and regulators won’t accept in the future). We will continue to innovate rapidly, expanding our offerings (breadth of algorithms) and improving performance (through continuous learning) so that we stay a step ahead of others. If a potential competitor emerges with a complementary strength, MAIVAN can consider strategic partnerships or acquisitions to integrate rather than fight – our platform is flexible to host others’ algorithms if they meet our standards, which means we could potentially turn some competitors into collaborators (e.g. if a new startup has a great spine surgery AI, we can validate and include it on MAIVAN rather than compete head-on). Finally, the market is large and at early stages – our focus is to move fast to capture mindshare and market share (landgrab strategy), leveraging our first-mover advantages in the validated orthopedic AI niche.

• Execution & Scaling Risk
  • Risk: Executing our plan – from product development to sales – in the complex healthcare environment is challenging. Sales cycles with hospitals can be long (12-18 months), integration at each site takes effort, and scaling internationally adds operational complexity (regulatory approvals in multiple jurisdictions, localization, etc.). If we underestimate these, growth could be slower than projected.
  • Mitigation: We are mitigating execution risk through focus and partnerships. Initially, we focus on a subsegment (orthopedic trauma and imaging in select regions) to ensure we nail the product-market fit before broad expansion. We also leverage existing networks to accelerate sales – for instance, the myAO community gives us direct access to thousands of surgeons who can champion MAIVAN in their hospitals​, bypassing some traditional sales hurdles. Our partnership with the University of Basel and others provides reference sites that we can showcase to new prospects, reducing the “wait and see” attitude among potential customers. To manage integration efficiently, we are building standardized deployment packages and have integration engineers who specialize in the major hospital IT systems – this streamlines the install at each new site (with playbooks for integration testing, staff training, etc.). Internationally, we will hire local experts/consultants for key markets to navigate compliance and language/cultural aspects rather than try to do it all centrally. The staged fundraising also means we won’t stretch too thin – we’ll scale the team and geographic reach in proportion to our capacity. Essentially, we plan to grow in phases, using the learnings from early deployments to refine and template our processes for later ones. With each successful implementation, our credibility and playbook strengthen, making the next one easier. The presence of experienced industry advisors on our team helps anticipate and avoid pitfalls that a less seasoned startup might hit. We consider execution discipline as important as innovation – and have project management in place for both product development and deployment efforts to keep us on track.

Go-To-Market Strategy

MAIVAN’s go-to-market strategy is a blend of leveraging our unique community assets, forging strategic partnerships, and targeted sales to early adopters in a phased approach. Here’s how we plan to acquire customers and scale:

• Phase 1 – Clinical Validation & Pilot Sites: We are currently in this phase. We have launched pilot programs at leading orthopedic centers such as University Hospital Basel (Switzerland) and Karolinska Institute (Sweden), where our solutions are being trialed in real patient care. The goal is to demonstrate efficacy and refine the user experience with frontline feedback. During this phase, we gather outcome data (e.g. how much did diagnostic accuracy improve? how did it affect surgical planning time?) to build case studies. These prestigious pilot sites also serve as reference accounts – seeing MAIVAN in action at top-tier institutions lends confidence to others. We aim to convert these pilots into paying customers once validation is complete, which would give us our first revenue and success stories.

• Phase 2 – Leverage Community & KOL Advocacy: With pilot results in hand, we will harness the power of our orthopedic surgeon community for broader outreach. MAIVAN has direct access to the myAO network of 90,000+ orthopedic surgeons​ and ties to EFORT and AOSSM, whose memberships represent the majority of orthopedic specialists in Europe and the U.S. respectively. We will organize webinars, panel discussions, and training sessions in collaboration with these associations to showcase MAIVAN’s capabilities. Key Opinion Leaders (KOLs) who were involved in the validation (surgeons who endorse the AI after seeing the benefits) will be front and center in these efforts. The idea is to create buzz and peer influence: surgeons trust other surgeons, so if the chiefs at Basel and Karolinska (for example) speak about how MAIVAN improved their practice, peers will take notice. We’ll also present our clinical results at major conferences (e.g. EFORT Annual Congress, AAOS meetings), and publish in orthopedic journals – positioning MAIVAN as the thought leader in AI for orthopedics. This stage is about generating demand pull: having clinicians ask their hospitals for MAIVAN because they’ve heard about its success.

• Phase 3 – Direct Sales and Partnerships for Adoption: In parallel with Phase 2, we will build a small but focused sales team to engage hospital decision-makers (department heads, CMIOs, CIOs, etc.). Our sales strategy emphasizes the value-based aspect – we will target progressive healthcare systems that are known for innovation or are under mandates to improve quality/cost (for instance, integrated delivery networks, large trauma centers, or networks in value-based care arrangements). We will use the data from pilots to make a clear ROI case: e.g., “Using MAIVAN could reduce your surgical complication costs by X and save Y clinician hours, which in dollar terms is $Z in savings – far exceeding our fees.” Having outcome-based pricing helps here, as we can say “pay us only if we deliver results,” making it a no-brainer to try. Additionally, partnerships will amplify our reach: we plan to partner with orthopedic implant manufacturers and surgical robotics companies to bundle our AI insights with their product offerings. For example, an implant company could offer MAIVAN’s planning software alongside their implants to help surgeons select the right implant size/type (benefiting the company through better outcomes and differentiating their product). Such partnerships give us access to established sales channels and customer bases. Similarly, we’ll look at partnering with hospital software vendors (PACS/EHR providers) to integrate MAIVAN as a module they can sell to their existing clients. A key partnership already in place is with cloud providers – through Google’s Marketplace, for instance, a hospital could deploy MAIVAN’s solution on their cloud with a few clicks, greatly simplifying procurement and deployment.

• Phase 4 – Scaling Up & Geographic Expansion: Once we have our first wave of adopter hospitals and demonstrated success, we will scale both depth (more hospitals in existing markets) and breadth (new regions). In Europe, we will leverage EFORT’s network to approach national health systems (for instance, NHS hospitals in the UK or university hospitals in Germany/France which often pilot innovations from EFORT initiatives). In the U.S., we will use AOSSM connections to get into sports medicine and large orthopedic group practices, and also pursue partnerships with major hospital networks and Accountable Care Organizations that focus on musculoskeletal care. By this stage, we anticipate word-of-mouth within the orthopedic community to significantly shorten our sales cycle – as more success stories circulate, late adopters will feel the pressure not to fall behind. For new global markets (Asia-Pacific, Middle East), we will identify key opinion leader institutions (like top orthopedic hospitals in India, China, etc.) and replicate the pilot-to-advocate model there. We may also align with international programs (for example, WHO initiatives on bone & joint health, or global telemedicine providers) to enter emerging markets with a value angle (AI can help areas with physician shortages). Our platform being cloud-based means we can deploy remotely; we will, however, ensure compliance with each country’s data laws by potentially hosting data in-region or partnering with local cloud providers as needed. To support expansion, we’ll establish regional offices or distributor agreements, and our materials will be translated/localized. The global need for orthopedic care is universal, so we foresee MAIVAN eventually having a presence wherever orthopedics is practiced – our strategic expansion will be methodical, tapping networks and ensuring quality control at each step.

• Retention & Growth: Acquiring customers is one side; we also emphasize retaining and growing within accounts. Our customer success team will work closely with each hospital to monitor usage and outcomes, ensuring they realize the full value. Satisfied customers will expand usage (more departments, more modules) and serve as reference sites for others. We’ll create a user community forum where different hospitals can share experiences – further binding customers to MAIVAN as not just a vendor, but a partner in innovation. Over time, this could evolve into user groups that meet annually, providing us feedback and evangelizing on our behalf.

Overall, our go-to-market approach is highly leveraged on relationships and proven value rather than broad, expensive advertising. By turning surgeons into our evangelists and partners into our channel, we can scale efficiently and credibly. Each new market entry is seeded with influencers and validated results to win trust quickly. This strategic approach will drive MAIVAN’s adoption from a handful of pilots to a global network of users in the coming years.

Let’s transform healthcare together. We welcome your questions and look forward to discussing how MAIVAN can deliver exceptional value for surgeons, hospitals, and millions of patients worldwide.

join@maivan.ai